Nuveen Asset Management LLC grew its stake in shares of HUTCHISON CHINA/S (NASDAQ:HCM) by 5.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,860 shares of the company’s stock after acquiring an additional 8,920 shares during the quarter. Nuveen Asset Management LLC owned about 0.13% of HUTCHISON CHINA/S worth $3,175,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its position in HUTCHISON CHINA/S by 109.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,677 shares of the company’s stock valued at $43,000 after buying an additional 875 shares during the last quarter. Quadrant Capital Group LLC purchased a new stake in HUTCHISON CHINA/S in the 4th quarter worth approximately $68,000. Shell Asset Management Co. boosted its position in HUTCHISON CHINA/S by 91.4% in the 1st quarter. Shell Asset Management Co. now owns 9,007 shares of the company’s stock worth $161,000 after purchasing an additional 4,300 shares in the last quarter. Krane Funds Advisors LLC boosted its position in HUTCHISON CHINA/S by 31.3% in the 1st quarter. Krane Funds Advisors LLC now owns 11,440 shares of the company’s stock worth $204,000 after purchasing an additional 2,727 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in HUTCHISON CHINA/S in the 4th quarter worth approximately $226,000. Hedge funds and other institutional investors own 30.90% of the company’s stock.
HCM has been the topic of several recent research reports. Zacks Investment Research lowered HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub upgraded HUTCHISON CHINA/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, Cantor Fitzgerald began coverage on HUTCHISON CHINA/S in a research report on Thursday, March 12th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $26.50.
Shares of NASDAQ:HCM opened at $28.05 on Wednesday. HUTCHISON CHINA/S has a 1 year low of $14.74 and a 1 year high of $29.92. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of -35.06 and a beta of 1.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.80 and a quick ratio of 2.66. The business’s 50 day moving average price is $22.83 and its 200-day moving average price is $23.08.
HUTCHISON CHINA/S Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Further Reading: Straddles
Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.